Abstract Library

#4625 Efficacy and safety of capecitabine-temozolomide (CAPTEM) regimen in patients with neuroendocrine neoplasms – A systematic review and experience from NETwerk, a Belgian ENETS Center of Excellence

Introduction: Current treatment guidelines remain inconclusive due to scarcity of data regarding the optimal systemic treatment for metastatic gastroenteropancreatic (GEP) neuroendocrine tumours (NET) grade 3 and aggressive GEP-NET grade 2. Similarly, for metastatic pulmonary typical (TC) and atypical carcinoids (AC), the indication for chemotherapy is unclear. Recent evidence highlights a promising role for CAPTEM, combining temozolomide (TEM) with capecitabine (CAP), showing encouraging antitumoural activity and safety profiles for these indications.

Conference:

Presenting Author: Chhajlani S

Authors: Chhajlani S, Lambrechts C, Islam O, de Weerdt C, Verbruggen L,

Keywords: capecitabine, temozolomide, CAPTEM, GEP-NET, pulmonary NEN, safety, efficacy, systematic review,

#4608 A complex and rare association of neuroendocrine and endocrine neoplasms: A case report

Introduction: Neuroendocrine tumours (NETs) are sporadic or genetically inherited heterogenous neoplasms affecting multiple sites.

Conference:

Presenting Author: Cerroni L

Authors: Cerroni L, Filice A, Feola T, Sesti F, Vincenzi L,

Keywords: cushing disease, atypical carcinoid, ileal net, genetics,

#4594 RNA splicing as a key regulatory player with translational potential in pulmonary neuroendocrine neoplasms (lungNETs)

Introduction: Neuroendocrine tumours (NETs) are a diverse group of neoplasms arising from neuroendocrine cells. Within this group, lung neuroendocrine tumours (LungNETs) represent one of the most frequent subtypes of NETs. LungNETs are classified by grade, according to their proliferative index and aggressiveness. Among them, typical carcinoids (G1) and atypical carcinoids (G2) are the lowest grade subtypes. While these tumours are less aggressive, they remain underexplored compared to higher-grade subtypes, highlighting the need for molecular studies to improve clinical approaches. In this context, previous studies have shown that abnormalities in the splicing machinery are frequent in tumour pathologies and also occur in LungNETs.

Conference:

Presenting Author:

Authors: Gutiérrez Camacho L, Ruiz-Palacios D, García Vioque V, González-Pérez C, Moreno Montilla M,

Keywords: splicing, neuroendocrine tumour, Lung NET, typical carcinoid, atypical carcinoid,

#4536 Follow-up is not justified in patients with typical lung carcinoids treated with curative intent

Introduction: Typical carcinoids (TC) are well-differentiated neuroendocrine neoplasms of the lung with generally favourable prognosis. Recurrence is rare in TC patients treated with curative intent, yet current ENETS guidelines recommend extensive follow-up, including regular and long-term imaging.

Conference:

Presenting Author: Lau T

Authors: Lau T, Soldath P, Rewitz K, Jepsen P, Knigge U,

Keywords: typical carcinoid, lung nen, follow-up programme,

#4446 Uncommon ophthalmic presentation of a small bowel neuroendocrine tumour: Case report

Introduction: Neuroendocrine tumours (NETs), including carcinoid tumours, are slow-growing neoplasms commonly originating in the gastrointestinal tract or bronchus, but they can also arise in other sites. Due to their indolent nature, the majority of NETs are diagnosed at an advanced stage, typically to the lymph nodes, liver, or bones.

Conference:

Presenting Author:

Authors: Hamidatou K, Behourah Z, Ahed Messaoud M, Megaiz A, Lechar M,

Keywords: Neuroendocrine tumour, Carcinoid tumour, Orbital metastasis, somatostatin analogue injection,